Answers are grounded in this paper and cite their sources.
Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring. (Funded by Ionis Pharmaceuticals; NEURO-TTR ClinicalTrials.gov number, NCT01737398 .).
No takes yet. Share an insight, caveat, or question.
Benson et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: